Advertisement

Picture [LSG] Life-Sciences-Germany.com – The Business Web Portal 600x80px
Document › Details

Compugen Ltd.. (11/2/17). "Press Release: Compugen to Enter Research Collaboration with Mount Sinai on Novel Myeloid Immuno-Oncology Targets". Holon.

Organisations Organisation Compugen Ltd. (Nasdaq: CGEN)
  Group Compugen (Group)
  Organisation 2 Mount Sinai School of Medicine (New York)
  Group Mount Sinai Health System (New York)
Products Product cancer immunotherapy (immuno-oncology, I-O)
  Product 2 drug target (research)
Person Person Cohen-Dayag, Anat (Compugen 201112 CEO)
     


Multi-year collaboration led by Dr. Miriam Merad


Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the initiation of a multi-year cancer immunotherapy research collaboration with Mount Sinai, under the direction of Miriam Merad, MD, PhD, Director of the Precision Immunology Institute and Co-Leader of the Cancer Immunology program and Mount Sinai Professor in Cancer Immunology at the Icahn School of Medicine at Mount Sinai in New York. Dr. Merad is a world-class leader in the field of myeloid biology for the development of novel cancer immunotherapies and is a member of Compugen’s Scientific Advisory Board (SAB).

Dr. Merad said, “After joining Compugen’s SAB earlier this year, I grew more familiar with and impressed by the Company’s promising novel immuno-oncology drug target pipeline. I am looking forward to collaborating with Compugen scientists in advancing the Company’s myeloid target candidates portfolio. Targeting myeloid biology, through Compugen myeloid target candidates, may potentially elicit a strong anti-tumor effect. Therapeutic development against myeloid targets can potentially provide a solution for cancer patients non-responsive to current treatments or serve as a combination therapy with existing immune checkpoint inhibitors in order to increase their response rate.”

Anat Cohen-Dayag, PhD, President and CEO of Compugen stated, “Following our fruitful multiyear collaboration with Johns Hopkins University School of Medicine, we are pleased to announce yet another research collaboration with a leading academic institution led by a worldrenowned expert in her field in order to further understand and advance our novel immunooncology targets towards clinical trials. We look forward to collaborating with Dr. Merad and her team and believe that this partnership will potentially broaden our pipeline and provide new treatment options for patients whose disease is refractory to existing immune checkpoint inhibitors or other treatment modalities.”

The collaboration will focus on the research and target validation of selected myeloid candidates discovered by Compugen for their potential to serve as a basis for cancer immunotherapy treatments, including the validation of their role in innate immunity and involvement in tumor biology.

“Mount Sinai is a robust ecosystem for the development of groundbreaking technologies that benefit patients on a global scale. It’s through the discoveries of talented translational innovators like Dr. Merad that we are able to continuously improve health outcomes,” said Erik Lium, PhD, Senior Vice President of Mount Sinai Innovation Partners.


About Myeloid Cells and Immunotherapy

Myeloid cells are a critical component of the immunosuppressive tumor microenvironment (TME), preventing T cells from entering the tumor and eliciting an immune response against the tumor. Targeting tumor myeloid cells may create an immune response towards the cancer, which has emerged as a complimentary strategy of multiple cancer immunotherapy approaches. This method can potentially elucidate a strong anti-tumor effect transforming a cold, or uninflamed tumor into a hot, or inflamed tumor. Therefore, it can potentially provide a solution for nonresponsive patients or serve as a combination therapy with existing immune checkpoint therapies in order to increase their response rate.


About Compugen

Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company’s therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen’s business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with R&D facilities in both Israel and South San Francisco, CA. Compugen’s shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.


About Mount Sinai Innovation Partners (MSIP)

MSIP is responsible for driving the real-world application and commercialization of Mount Sinai discoveries and inventions, and the development of research partnerships with industry. Our aim is to translate discoveries and inventions into health care products and services that benefit patients and society. MSIP is accountable for the full spectrum of commercialization activities required to bring Mount Sinai inventions to life. These activities include evaluating, patenting, marketing and licensing new technologies building research, collaborations and partnerships with commercial and nonprofit entities, material transfer and confidentiality, coaching innovators to advance commercially-relevant translational discoveries, and actively fostering an ecosystem of entrepreneurship within the Mount Sinai research and health system communities. For more information, visit www.ip.mountsinai.org.


Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” “potential,” “plan,” “goal,” “estimate,” “likely,” “should,” and “intends,” and describe opinions about possible future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen’s business model is substantially dependent on entering into collaboration agreements with third parties, Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors are more fully discussed in the "Risk Factors" section of Compugen’s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.


Company contact:
Elana Holzman Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972 (3) 765-8124

Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Email: jsteier@burnsmc.com
Tel: 212-213-000

   
Record changed: 2017-11-17

Advertisement

Picture [LSF] Life-Sciences-France.com – The Business Web Portal 600x80px

More documents for Compugen (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Biotech Showcase 2018 BTS San Francisco January 120x180px